Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: A clinical phase 1/2 trial

Journal of Immunotherapy

Volumn 31, Issue 8, 2008, Pages 771-780

  Berntsen, Annika ^a   Trepiakas, Redas ^a   Wenandy, Lynn ^a   Geertsen, Poul F ^a   Straten, Per Thor ^a   Andersen, Mads H ^a   Pedersen, Anders E ^a   Claesson, Mogens H ^a   Lorentzen, Torben ^a   Johansen, Julia S ^b   Svane, Inge Marie ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer vaccination; Dendritic cell; IL 6; Renal cell carcinoma; YKL 40

Indexed keywords

BIOLOGICAL MARKER; DENDRITIC CELL VACCINE; HLA A2 ANTIGEN; IMIQUIMOD; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 2; SURVIVIN; TELOMERASE; UNCLASSIFIED DRUG; YKL 40; BIRC5 PROTEIN, HUMAN; CANCER VACCINE; CHI3L1 PROTEIN, HUMAN; GLYCOPROTEIN; INTERLEUKIN 2; MICROTUBULE ASSOCIATED PROTEIN; PEPTIDE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYTOTOXIC T LYMPHOCYTE; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FLUORESCENCE ACTIVATED CELL SORTING; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; KIDNEY CARCINOMA; LOW DRUG DOSE; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SWEATING; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; ADOPTIVE IMMUNOTHERAPY; AMINO ACID SEQUENCE; BLOOD; DENDRITIC CELL; IMMUNOLOGY; KAPLAN MEIER METHOD; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; MOLECULAR GENETICS; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE; VACCINATION;

ADULT; AGED; AMINO ACID SEQUENCE; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; INTERLEUKIN-6; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TELOMERASE; VACCINATION;

EID: 59849105579     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181833818     Document Type: Article

References (53)

1. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol. 1999;161:381-386.
2. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005;CD001425.
3. Motzer RJ. Renal cell carcinoma: a priority malignancy for development and study of novel therapies. J Clin Oncol. 2003;21:1193-1194.
4. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
6. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
7. Berntsen A, Geertsen PF, Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol. 2006;50:34-43.
8. Andersen MH, Pedersen LO, Becker JC, et al. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001;61:869-872.
9. Vonderheide RH, Domchek SM, Schultze JL, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004;10:828-839.
10. Reichardt VL, Brossart P, Kanz L. Dendritic cells in vaccination therapies of human malignant disease. Blood Rev. 2004;18:235-243.
11. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2:619-626.
12. Johansen JS, Jensen BV, Roslind A, et al. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006;15:194-202.
13. Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992;52:3317-3322.
14. Stadler WM, Richards JM, Vogelzang NJ. Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst. 1992;84:1835-1836.
15. Dupont J, Latouche JB, Ma C, et al. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res. 2005;65:5417-5427.
16. Maecker B, Bergwelt-Baildon MS, Anderson KS, et al. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin Exp Immunol. 2005;141:558-562.
17. Gross DA, Graff-Dubois S, Opolon P, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest. 2004;113:425-433.
18. Thorn M, Wang M, Kloverpris H, et al. Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope. Cancer Immunol Immunother. 2007;56:1755-1763.
19. Vonderheide RH, Anderson KS, Hahn WC, et al. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res. 2001;7:3343-3348.
20. Schroers R, Huang XF, Hammer J, et al. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res. 2002;62:2600-2605.
21. Schroers R, Shen L, Rollins L, et al. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res. 2003;9:4743-4755.
22. Andersen MH, Pedersen LO, Capeller B, et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001;61:5964-5968.
23. + T cells in colorectal cancer patients. Cancer Res. 2003;63:4507-4515.
24. Reker S, Meier A, Holten-Andersen L, et al. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther. 2004;3:173-179.
25. Reker S, Becker JC, Svane IM, et al. HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer. 2004;108:937-941.
26. Alexander J, Fikes J, Hoffman S, et al. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol Res. 1998;18:79-92.
27. Johnston D, Bystryn JC. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine. 2006;24:1958-1965.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
29. Andersen MH, Reker S, Kvistborg P, et al. Spontaneous immunity against Bcl-xL in cancer patients. J Immunol. 2005;175:2709-2714.
30. Meier A, Reker S, Svane IM, et al. Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients. Cancer Immunol Immunother. 2005;54:219-228.
31. Harvey S, Weisman M, O'Dell J, et al. Chondrex: new marker of joint disease. Clin Chem. 1998;44:509-516.
32. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53:172-209.
33. Knudsen LS, Christensen IJ, Lottenburger T, et al. Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers. 2008;13:59-78.
34. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
35. Trepiakas R, Pedersen AE, Met Ö, et al. Comparison of α-type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Vaccine. 2008;26:2824-2832.
36. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141.
37. Geertsen PF, Gore ME, Negrier S, et al. Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer. 2004;90:1156-1162.
38. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454-463.
39. de Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003;63:12-17.
40. Prins RM, Craft N, Bruhn KW, et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006;176:157-164.
41. Kyte JA, Mu L, Aamdal S, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 2006;13:905-918.
42. Bedrosian I, Mick R, Xu S, et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8 + T-cell function in melanoma patients. J Clin Oncol. 2003;21:3826-3835.
43. Su Z, Dannull J, Yang BK, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol. 2005;174:3798-3807.
44. Wobser M, Keikavoussi P, Kunzmann V, et al. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother. 2006;55:1294-1298.
45. Berger TG, Haendle I, Schrama D, et al. Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells. Int J Cancer. 2004;111:229-237.
46. Negrier S, Perol D, Menetrier-Caux C, et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 - from the Groupe Francais d'Immunotherapie. J Clin Oncol. 2004;22:2371-2378.
47. Menetrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood. 1998;92:4778-4791.
48. Menetrier-Caux C, Thomachot MC, Alberti L, et al. IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res. 2001;61:3096-3104.
49. Menetrier-Caux C, Bain C, Favrot MC, et al. Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes. Br J Cancer. 1999;79:119-130.
50. Johansen JS, Stoltenberg M, Hansen M, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford). 1999;38:618-626.
51. Vind I, Johansen JS, Price PA, et al. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol. 2003;38:599-605.
52. Schmidt H, Johansen JS, Gehl J, et al. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 2006;106:1130-1139.
53. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115:3623-3633.